Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAX-XL
- Development stage
- Preclinical
- Lead developer
- Vaxcyte
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VAX-XL is a third-generation pneumococcal conjugate vaccine (PCV) candidate being developed by Vaxcyte. It is designed to provide the broadest coverage of any PCV currently in development, targeting a wide range of Streptococcus pneumoniae serotypes responsible for invasive pneumococcal disease (IPD), including meningitis and bacteremia. The vaccine uses advanced synthetic techniques and the XpressCF cell-free protein synthesis platform to produce high-fidelity proteins and antigens, aiming to improve immunological benefits over existing vaccines. As of May 2025, VAX-XL remains in preclinical development for the prevention of pneumococcal infections[1][3][8][9].
- Brand names
- VAX-XL
- Other names
- Third-generation pneumococcal conjugate vaccineThird-generation PCV vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on VAX-XL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAX-XL.